Iekopēju GTP4o ģenerēto sarakstiņu ar tekošajām firmām un zālītēm, kas to pēta:

1. Acceleron Pharma
Drug: ACE-083
Mechanism: Myostatin inhibitor
Status: Acceleron has been investigating myostatin inhibitors for muscle growth in conditions like neuromuscular diseases.
2. Axcella Health
Drug: AXA1125 and AXA1957
Mechanism: Multifactorial metabolic modulators designed to improve muscle health and metabolic function.
Status: These drugs are in clinical development for metabolic diseases, including muscle atrophy.
3. Bayer
Drug: BAY 85-3934 (Molidustat)
Mechanism: PHD inhibitor that can potentially improve oxygen delivery and muscle function.
Status: Under investigation for anemia related to chronic kidney disease but has implications for muscle health.
4. CohBar
Drug: CB4211
Mechanism: Mitochondrial-derived peptide designed to improve insulin sensitivity and metabolic function.
Status: In early-stage clinical trials for metabolic diseases, with potential benefits for muscle health.
5. Novartis
Drug: Bimagrumab
Mechanism: Anti-myostatin monoclonal antibody.
Status: Initially developed for muscle-wasting diseases; now being explored for obesity and metabolic disorders.
6. Pfizer
Drug: PF-06252616 (Domagrozumab)
Mechanism: Myostatin inhibitor.
Status: Under development for Duchenne muscular dystrophy but has broader implications for muscle growth.
7. Amgen
Drug: AMG 745 (Trepidermin)
Mechanism: Myostatin pathway inhibitor.
Status: Amgen has been exploring various approaches to modulate muscle growth, including myostatin inhibition.
8. Mitobridge (Astellas)
Drug: MA-0211 (also known as ASP0367)
Mechanism: PPAR delta agonist.
Status: Focused on improving mitochondrial function and treating muscle diseases, including sarcopenia.
9. Regeneron Pharmaceuticals
Drug: REGN2477 (Garetosmab)
Mechanism: Myostatin inhibitor.
Status: Investigated for fibrodysplasia ossificans progressiva, a condition involving abnormal muscle growth.
10. Sarcopenia Therapeutics
Drug: Various compounds
Mechanism: Focused on developing therapies specifically targeting age-related muscle loss.
Status: Early-stage development and research.
11. Ligand Pharmaceuticals
Drug: VK5211 (LGD-4033)
Mechanism: Selective androgen receptor modulator (SARM)
Status: In clinical trials for muscle wasting and hip fracture recovery.